Bergen Bio ASA’s Axl kinase blocker bemcentinib in combination with MSD’s pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).

German researchers have designed a modified Sleeping Beauty transposase that can be used for non-viral, stable and efficient gene insertions for gene and CAR-T therapies.

Despite challenging markets new players are entering the field to advance drug development in the fight against antimicrobial resistance.

Renowned immunologist Iain McInnes has been appointed to the Scientific Advisory Boar of Oxford BioDynamics Plc, where he joins Karol Sikora, Jane Mellor and Lucien Peng-Jin Ooi.

Breast cancer might be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced by tumour cells.

BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps.

Synbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource settings.

German researchers have shown that a protein protects against the development of liver fibrosis by shutting down inflammatory signalling in liver stellate cells of the liver. 

Cell reprogramming specialist bit bio has expanded its management with renowned experts in the field.

Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to develop novel anti-virulence antibiotics to treat severe bacterial infections.